Instrument Inactif

Communiqués Bioverativ Inc

Actions

US09075E1001

Recherche biotechnologique et médicale

Communiqués

06/03/18	Bioverativ : Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease	BU
14/02/18	Bioverativ : Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A	BU
13/02/18	Bioverativ : Reports Fourth Quarter and Full Year 2017 Performance	BU
24/01/18	The Law Offices of Vincent Wong : Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi	BU
24/01/18	WeissLaw LLP : Investigates Bioverativ Inc. Acquisition	PR
23/01/18	Rigrodsky & Long, P.A. Announces Investigation of Bioverativ Inc. Buyout	BU
23/01/18	Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders	BU
22/01/18	Bragar Eagel & Squire, P.C. : is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of Stockholders and Encourages Investors to Contact the Firm	BU
22/01/18	BIOVERATIV INC. Rigrodsky & Long, P.A. Announces Investigation of Buyout	BU
22/01/18	Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders – BIVV	BU
16/01/18	Bioverativ : to Report Fourth Quarter and Year-End 2017 Financial Results on February 13, 2018	BU
02/01/18	Bioverativ : to Present at the 2018 J.P. Morgan Healthcare Conference	BU
22/12/17	Bioverativ : Announces 2018 Annual Meeting of Stockholders	BU
11/12/17	Bioverativ : Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients	BU
11/12/17	Bioverativ : New Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe and Effective Protection in People with Severe Hemophilia B	BU
10/12/17	Bioverativ : Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A	BU
09/12/17	Bioverativ : ALPROLIX® Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study	BU
27/11/17	Bioverativ : U.S. Label Update for ALPROLIX® Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children with Hemophilia B	BU
21/11/17	Bioverativ : to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference	BU
01/11/17	Bioverativ : to Present at the Credit Suisse 2017 Healthcare Conference	BU
01/11/17	Bioverativ : to Present New Data on Rare Blood Disorder Programs at ASH 2017 Annual Meeting	BU
31/10/17	Bioverativ : Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for Hemophilia A Patients Following Prophylactic Treatment with ELOCTATE®	BU
26/10/17	Bioverativ : Reports Third Quarter 2017 Performance	BU
02/10/17	Bioverativ : Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia	PR
28/09/17	Bioverativ : to Report Third Quarter 2017 Financial Results on October 26, 2017	BU